ClinicalTrials.gg
CompletedNCT07849309Updated Sep 30, 2026

Real-World Incidence of Intraocular Inflammation Following Intravitreal Treatment With Aflibercept 8 mg

An observational study in Intraocular Inflammation and Intravitreal Injections, sponsored by Copenhagen University Hospital, Rigshospitalet. Completed at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Copenhagen University Hospital, Rigshospitalet · Observational

How we know

Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
3,690
Ages
18 Years and older
Sex
All
01

Study summary

Aflibercept 8 mg is a high-concentration anti-vascular endothelial growth factor therapy developed to extend treatment intervals for retinal diseases while maintaining the efficacy and safety of aflibercept 2 mg. Phase 3 trials supported its use in neovascular age-related macular degeneration, diabetic macular edema, and retinal vein occlusion.

The aim of this study was to estimate the incidence of intraocular inflammation (IOI) after intravitreal aflibercept 8 mg injections in an unselected cohort treated at a large tertiary referral center, and describe the presentation, management and outcome of the affected eyes.

02

Conditions studied

  • Intraocular Inflammation
  • Intravitreal Injections

Browse trials for

Keywords

  • adverse event
  • aflibercept 8 mg
  • anti-VEGF
  • intraocular inflammation
  • intravitreal injection
  • real-world data
03

In context

Uveitis

300 studies on the registry are indexed under Uveitis; 33 are open to participants now.

This study's enrollment of 3,690 is above the median of 114 across 105 observational studies indexed under Uveitis.

Browse Uveitis studies →

Lead sponsor

Copenhagen University Hospital, Rigshospitalet is the lead sponsor of 46 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Consecutive patients who received at least 1 intravitreal aflibercept 8mg injection between 01/DEC/2024 and 30/NOV/2025 at the Department of Ophthalmology, Rigshospitalet, Denmark

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • >18 years of age
  • Have received at least 1 intravitreal aflibercept 8mg injection at our center
  • Follow-up period of at least 6 weeks after the injection

Exclusion criteria

Exclusion Criteria:

  • Patients with incomplete medical records
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
3,690 participants (actual)
Patient registry
No

Groups and cohorts

  • Received aflibercept 8mg intravitreal injections

    Drug: Aflibercept (Eylea)

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of IOI following an intravitreal aflibercept 8 mg injection

    Reported per patient, per eye and per injection

    Time frame: 01/DEC/2024 - 30/NOV/2025

Secondary outcomes

  1. Anatomical IOI phenotype

    Described after the SUN classification system

    Time frame: 01/DEC/2024 - 30/NOV/2025

  2. Time from injection to IOI symptom onset

    Described in days

    Time frame: 01/DEC/2024 - 30/NOV/2025

  3. Disease duration of IOI

    Described in days

    Time frame: 01/DEC/2024 - 30/NOV/2025

  4. Treatment strategy after the IOI event

    Description of the type of drug or intervention used

    Time frame: 01/DEC/2024 - 30/NOV/2025

  5. Functional outcome after the IOI event

    Described in logMAR best-corrected visual acuity

    Time frame: 01/DEC/2024 - 30/NOV/2025

Other outcomes

  1. Comparisons by demographic characteristics, diagnosis and treatment status

    Described as exploratory descriptive analysis

    Time frame: 01/DEC/2024 - 30/NOV/2025

07

Study locations

1 site
  • Rigshospitalet, Department of Ophthalmology
    Glostrup Municipality, 2600, Denmark
08

References and documents

Individual participant data

Plan to share: No — Raw data sharing with third parties was not approved for this project.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2026 to primary completion in Aug 2026, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2026
First posted
Sep 30, 2026
StartActual
Apr 20, 2026
Primary completionActual
Aug 10, 2026
CompletionActual
Sep 14, 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07849309
Lead sponsor
Copenhagen University Hospital, Rigshospitalet
Responsible party
Miklos Schneider MD, PhD (Senior Consultant, Clinical Associate Professor, Copenhagen University Hospital, Rigshospitalet) — Principal investigator
First posted
Sep 30, 2026
Start date
Apr 20, 2026
Primary completion
Aug 10, 2026
Completion
Sep 14, 2026
Last update
Sep 30, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion